^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCAR4 overexpression

    i
    Other names: BCAR4, Breast Cancer Anti-Estrogen Resistance 4, BCAR4, Breast Cancer Anti-Estrogen Resistance 4 (Non-Protein Coding), Breast Cancer Antiestrogen Resistance 4 Protein, HCG1814062, Isoform CRA_a, NONHSAG018621.2, HSALNG0109621
    Entrez ID:
    400500
    over1year
    Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2. (PubMed, Front Mol Biosci)
    Library screening revealed that erlotinib, canertinib, and lapatinib demonstrated inhibitory effects on cell migration. In addition, canertinib treatment restored E-cadherin expression and reduced the expression of epithelial-mesenchymal transition regulatory factors such as Slug and Snail. Taken together, these results suggest that EGFR/HER2 inhibitors are potential therapeutic options for BCAR4 fusion-harboring lung cancer patients, even in the absence of EGFR mutations.
    Journal
    |
    CDH1 (Cadherin 1) • BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) • SNAI2 (Snail Family Transcriptional Repressor 2)
    |
    CDH1 expression • BCAR4 overexpression
    |
    erlotinib • lapatinib • canertinib (CI-1033)
    almost2years
    Downregulation of long noncoding RNA breast cancer anti-estrogen resistance 4 inhibits cell proliferation, invasion, and migration in esophageal squamous cell carcinoma by regulating the microRNA-181c-5p/LIM and SH3 protein 1 axis. (PubMed, Bioengineered)
    Moreover, knockdown of BCAR4 and overexpression of miR-181c-5p inhibited the activation of the STAT3/COX2 signaling, which was reversed by overexpression of LASP1. In conclusion, BCAR4 promotes ESCC tumorigenesis by targeting the miR-181c-5p/LASP1 axis, which may act as a treatment and diagnosis biomarker for ESCC.
    Journal
    |
    BCAR4 (Breast Cancer Anti-Estrogen Resistance 4) • LASP1 (LIM And SH3 Protein 1) • MIR181C (MicroRNA 181c)
    |
    PTGS2 expression • BCAR4 overexpression
    almost3years
    The role of long non-coding RNA BCAR4 in human cancers. (PubMed, Hum Cell)
    Therefore, BCAR4 is a promising biomarker for cancer diagnosis and prognosis, and it is a potential target for cancer therapy. This paper reviews studies focusing on the relationship between BCAR4 and cancers in recent years and aims to summarize the effect and mechanism of BCAR4 in human cancers.
    Review • Journal
    |
    BCAR4 (Breast Cancer Anti-Estrogen Resistance 4)
    |
    BCAR4 overexpression